4.7 Review

Chronic Kidney Disease and Coronary Artery Disease

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 74, Issue 14, Pages 1823-1838

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.08.1017

Keywords

acute coronary syndromes; calcification; chronic kidney disease; coronary artery disease; revascularization

Funding

  1. Kidney Disease: Improving Global Outcomes
  2. Akebia Therapeutics
  3. Amgen
  4. Fresenius Medical Care
  5. Kyowa Kirin
  6. Abbott Vascular
  7. Pfizer
  8. Reata
  9. Boston Scientific
  10. Medtronic
  11. Siemens
  12. Novo Nordisk
  13. National Institutes of Health (NIH)
  14. Medicines Company
  15. Sanofi
  16. Roche Diagnostics
  17. Ortho Clinical Diagnostics
  18. Amylin and Boehringer Ingelheim
  19. AbbVie
  20. OxThera
  21. Bristol-Myers Squibb
  22. National Institute of Diabetes and Digestive and Kidney Diseases/NIH
  23. National Heart, Lung, and Blood Institute/NIH
  24. AstraZeneca
  25. Napp/Mundipharma
  26. Vifor Fresenius Medical Care Renal Pharma
  27. Mitsubishi Tanabe
  28. Pharmacosmos
  29. Daichii-Sankyo
  30. GE Medical Systems

Ask authors/readers for more resources

Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research. (C) Published by Elsevier on behalf of the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available